Claims for Patent: 9,101,669

Summary for Patent: 9,101,669

Title:	Self-assembed conjugate and use thereof
Abstract:	Provided are a self-assembled conjugate of a host molecule containing compound and a guest molecule containing compound, a delivery composition of a bioactive material comprising the self-assembled conjugate and a bioactive material to be delivered, and a composition for tissue engineering containing the self-assembled conjugate and a cell.
Inventor(s):	Hahn; Sei Kwang (Pohang, KR), Kim; Kimoon (Pohang, KR), Jung; Hyuntae (Pohang, KR), Yang; Jeong-A (Cheongju, KR), Park; Kyeng Min (Pohang, KR)
Assignee:	POSTECH ACADEMY-INDUSTRY FOUNDATION (Pohang, KR)
Application Number:	13/362,205
Patent Claims:	1. A self-assembled conjugate comprising a compound of chemical formula I and a compound of chemical formula II: [B]m-[H]n, (chemical formula I) [B]m-[G]l; (chemical formula II) in chemical formula I and II, H is a cucurbit[n]uril n=5-12 having a functional group selected from the group consisting of an amine group, a carboxyl group, a hydroxyl group, an aldehyde group, an allyloxy group, a vinyl group, an acryl group, a thiol group, and a combination thereof; G is selected from the group consisting of a C1-C20 aminoalkyl group having at least one amine group and a C1-C20 aminoalkyl group having metallocene; B is a monomer of a polymer having a functional group selected from the group consisting of an amine group, a carboxyl group, a hydroxyl group, an aldehyde group, an allyloxy group, a vinyl group, an acryl group, a thiol group, and a combination thereof, wherein the polymer is at least one selected from the group consisting of polyethylene glycol (PEG), poly lactic acid (PLA), poly glycolic acid (PGA), poly lactic-co-glycolic acid (PLGA), hyaluronic acid, chitosan, dextran, and cellulose; m, which is the number of the monomer, is an integer from 1 to 10,000; and n and l, which are the mole number of the host molecule or the guest molecule, respectively, are independently selected from integers from 1 to 10,000, wherein the ratio of m:n or 1 is 1:0.2 to 1:1, and the ratio of n:1 is 1:0.1 to 1:10, and wherein the equivalent ratio between the compound of chemical formula I and a compound of chemical formula II is 1:0.1 to 1:10 (equivalent of the compound of chemical formula I:equivalent of the compound of chemical formula II). 2. The self-assembled conjugate according to claim 1, wherein H is a cucurbit[n]uril n=6 or 7 linked with a functional group selected from the group consisting of an amine group, a hydroxyl group, an allyloxy group, and a combination thereof. 3. The self-assembled conjugate according to claim 1, wherein G is selected from the group consisting of spermine (SPM), diaminohexane (DAH), ferrocene methylamine, and a combination thereof. 4. The self-assembled conjugate according to claim 1, wherein B is a hyaluronic acid liked with a functional group selected from the group consisting of an amine group, a carboxyl group, a hydroxyl group, an aldehyde group, an allyloxy group, a vinyl group, an acryl group, a thiol group, and a combination thereof. 5. The self-assembled conjugate according to claim 1, which is in an aqueous solution form wherein the concentration of the self-assembled conjugate is 2 to 10%(w/v) to form a hydrogel. 6. A method for preparing a delivery composition of a bioactive material, comprising the step of: providing a the self-assembled conjugate according to claim 1 and a bioactive material. 7. The method according to claim 6, wherein the bioactive material is at least one selected from the group consisting of a drug, a fluorescent material, a radioisotope, a target-oriented material, an imaging material, a cell, a protein drug, an antibody, and an aptamer. 8. The method according to claim 7, wherein the drug is at least one selected from the group consisting of paclitaxel, doxorubicin, docetaxel, 5-fluoreuracil, oxaliplatin, cisplatin, carboplatin, berberine, epirubicin, doxycycline, gemcitabine, rapamycin, tamoxifen, herceptin, avastin, tysabri, erbitux, campath, zevalin, humira, mylotarg, xolair, bexxar, raptiva, remicade, siRNA, aptamer, interferon, insulin, reopro, rituxan, zenapax, simulect, orthoclone, synagis, erythropoietin, epidermal growth factor (EGF), human growth hormone (hGH), thioredoxin, Fel d1, Bee Venom Phospholipase A2 (Api m1), myelin basic protein, Hsp60, and Chaperone DnaJ (Hsp 40). 9. The method according to claim 7, wherein the fluorescent material is at least one selected from the group consisting of fluorescein, rodamine, Dansyl, Cyanine dye (Cy), and antracene. 10. The method according to claim 7, wherein the radioisotope is at least one selected from the group consisting of .sup.3H, .sup.14C, .sup.22Na, .sup.35S, .sup.33P, .sup.32P, and .sup.125I. 11. The method according to claim 7, wherein the target-oriented material is a peptide comprising at least one selected from the group consisting of RGD (arginine-leucine-aspartic acid), TAT (threonine-alanine-threonine), and MVm (methionine-valine-D-methionine); a peptide recognizing a specific cell; an antigen; an antibody; folic acid; nucleic acid; an aptamer; and a carbohydrate. 12. The method according to claim 7, wherein the imaging material is at least one selected from the group consisting of a gadolinium (Ga)-complex selected from gadolinium-diethylenetriamine penta-acetic acid (Ga-DTPA), gadolinium-diethylenetriamine penta-acetic acid-BMA (Ga-DTPA-BMA), gadolinium-tetraazacyclododecanetetraacetic acid (Ga-DOT), and Gadolinium-(1,4,8,11-tetraazacyclotetradecane) (Ga-cyclam); a nanoparticle of a metal selected from gold, silver, manganese, cadmium, selenium, tellurium, zinc, which has an average diameter of 1 to 200 nm; and a carbon nano-material selected from a single-walled carbon nanotube, a multi-walled carbon nanotube, fullerene, and graphene. 13. The method according to claim 7, wherein the cell is at least one selected from the group consisting of cancer cells, bone cells, skin cells, stomach cells, intestinal cells, lung cells, liver cells, brain cells, blood endothelial cells, immune cells, eythrocytes, leukocytes, lymphocytes, preosteoblasts, osteoblast, mesenchymal stem cell, and induced pluripotent stem cell. 14. A composition for tissue engineering containing the self-assembled conjugate according to claim 1 and one or more selected from the group consisting of a cell, a cell-differentiation inducer, a cell-proliferation accelerator, a cell-growth factor, and a cell-adsorption inducer. 15. The composition for tissue engineering according to claim 14, wherein the cell is at least one selected from the group consisting of cancer cells, bone cells, skin cells, stomach cells, intestinal cells, lung cells, liver cells, brain cells, blood endothelial cells, immune cells, eythrocytes, leukocytes, lymphocytes, preosteoblasts, osteoblast, mesenchymal stem cell, and induced pluripotent stem cell.

Details for Patent 9,101,669

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	REOPRO	abciximab	Injection	103575	12/22/1994		2039-02-26
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2039-02-26
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2039-02-26
Hoffmann-la Roche Inc.	ZENAPAX	daclizumab	Injection	103749	12/10/1997		2039-02-26